P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19

Introduction: Covid-19 pandemic has drastically changed the management of patients with cancer;however, there is still limited data regarding the real impact of Covid-19 on patient’s outcomes due to delayed diagnosis and treatment of clinical complications We aimed to assess the prevalence, severity and mortality of clinical complications and oncology emergencies in hospitalized patients in our institution during the Covid19 period vs the same period of 2019 Methods: We conducted a retrospective study of patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) who were admitted to the Department of Medical Oncology during Jan-Jun 2019 (before-Covid) and Jan-Jun 2020 (Covid-19 period) Clinical, pathological and biological data were collected We assessed the clinical severity in both periods including: PS at admission, progression disease (PD), oncologic emergencies (%), start of a systemic therapy or switch to other therapy line We also analyzed the differences on the 30-day mortality rate since hospitalization between both periods Results: 229 admissions, 133 during and 93 before Covid-19 pandemic (N=180 patients) were enrolled;the median duration of the hospitalization was 9 days (4-16) Median age was 66 years, 35% were female, 88% with PS≥2, 27% were current smokers;83% had NSCLC histology Most of them (82%) had advanced disease at admission;69% were under systemic therapy (chemotherapy 39%, immunotherapy 17%, targeted therapies 11%) Nine patients (4%) were active covid-19 cases (9 NSCLC, 0 SCLC) The table 1 summarized the most common clinical conditions by histology, in both periods In NSCLC population, during-Covid, lower rate of admissions were observed (4 cases less per month), with no increase of oncologic emergencies The PD during hospitalization was slightly higher during vs before-Covid, but no differences were observed in 30-days mortality rate In SCLC population, during-Covid, the rate of admissions was doubled (2 cases more per month), with more cases progressing during the hospitalization (46% during vs 34% before-Covid) In contrast to NSCLC, the 30-days mortality rate was higher during-Covid (38%) vs before-Covid (20%) Updated data will be presented in the meeting [Formula presented] Conclusion: We preliminary observed more aggressive disease with worse outcomes in patients with SCLC hospitalized during-Covid compared to the same period in 2019 No differences were observed in NSCLC The final outcomes will be assessed in a larger and mature cohort still ongoing Keywords: lung cancer, COVID-19, hospitalization